<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; trend</title>
	<atom:link href="http://www.tapanray.in/tag/trend/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Multichannel Marketing: Two Important Pharma Trends</title>
		<link>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multichannel-marketing-two-important-pharma-trends</link>
		<comments>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/#comments</comments>
		<pubDate>Mon, 10 Sep 2018 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dinner]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCM]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[meetings]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[print]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9149</guid>
		<description><![CDATA[On September 6, 2018, Reuters reported the announcement of GlaxoSmithKline (GSK) that it would cut about 650 positions in the United States related to a global restructuring program. This includes 450 Medical (sales) Representatives (MR). Similar announcements on job cuts for MRs &#8230; <a href="http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making New Cancer Drugs Cost-effective</title>
		<link>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-new-cancer-drugs-cost-effective</link>
		<comments>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/#comments</comments>
		<pubDate>Mon, 17 Apr 2017 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[cost-effective]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repositioning]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[Sildenefil]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thalidomide]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[viagra]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8188</guid>
		<description><![CDATA[The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, &#8230; <a href="http://www.tapanray.in/making-new-cancer-drugs-cost-effective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access</title>
		<link>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-a-dangerous-pricing-trend-impacting-patient-access</link>
		<comments>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/#comments</comments>
		<pubDate>Mon, 11 Jul 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[Daniel]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irresponsible]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[profits]]></category>
		<category><![CDATA[ptent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Stone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7721</guid>
		<description><![CDATA[The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, &#8230; <a href="http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Democratization of Healthcare: An Evolving Trend Driven By Cutting-Edge Technology</title>
		<link>http://www.tapanray.in/democratization-of-healthcare-an-evolving-trend-driven-by-cutting-edge-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=democratization-of-healthcare-an-evolving-trend-driven-by-cutting-edge-technology</link>
		<comments>http://www.tapanray.in/democratization-of-healthcare-an-evolving-trend-driven-by-cutting-edge-technology/#comments</comments>
		<pubDate>Mon, 15 Feb 2016 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[Autism]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[cutting-edge]]></category>
		<category><![CDATA[deficit]]></category>
		<category><![CDATA[deities]]></category>
		<category><![CDATA[Democratization]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[empowering]]></category>
		<category><![CDATA[Eric]]></category>
		<category><![CDATA[evolutionary]]></category>
		<category><![CDATA[Health Apps]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jeff]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Operating]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Topol]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[Williams]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7433</guid>
		<description><![CDATA[We have stepped on to a fascinating era of yet another disruptive innovation in a newly carved out space of the healthcare domain. Such initiatives are driven by path breaking ideas, which are being translated into reality with the application &#8230; <a href="http://www.tapanray.in/democratization-of-healthcare-an-evolving-trend-driven-by-cutting-edge-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/democratization-of-healthcare-an-evolving-trend-driven-by-cutting-edge-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evolving Trend Of Patient Engagement In Treatment Decisions</title>
		<link>http://www.tapanray.in/evolving-trend-of-patient-engagement-in-treatment-decisions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=evolving-trend-of-patient-engagement-in-treatment-decisions</link>
		<comments>http://www.tapanray.in/evolving-trend-of-patient-engagement-in-treatment-decisions/#comments</comments>
		<pubDate>Mon, 06 Jul 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Health Apps]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed patients]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PCORI]]></category>
		<category><![CDATA[Pew Charitable Trusts]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment decision]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6789</guid>
		<description><![CDATA[Slowly but steadily the process of taking treatment decisions for the patients is undergoing a metamorphosis, where well informed patients no longer want to play just a passive role. These patients want the doctors to take a final decision on &#8230; <a href="http://www.tapanray.in/evolving-trend-of-patient-engagement-in-treatment-decisions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/evolving-trend-of-patient-engagement-in-treatment-decisions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global New Product Launches: Recent Success Trend Unflattering?</title>
		<link>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-new-product-launches-recent-success-trend-unflattering</link>
		<comments>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/#comments</comments>
		<pubDate>Mon, 24 Mar 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[2007]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[FirstWord]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[McKinsey]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[unflattering]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5132</guid>
		<description><![CDATA[New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&#38;D output in terms of &#8216;New Molecules&#8217;, followed by successful development and &#8230; <a href="http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Pool’ – is GSK setting a new trend for the global pharmaceutical industry?</title>
		<link>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 18 May 2009 00:30:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=884</guid>
		<description><![CDATA[On February 13, 2009, The Guardian reported that Andrew Witty, CEO of GlaxoSmithKline (GSK) announced some significant changes to the way his company will operate in the developing countries of the world. GSK, as Witty said, will: • “Cut its &#8230; <a href="http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-pool-is-gsk-setting-a-new-trend-for-the-global-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
